Trial Profile
An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Registrational
- Sponsors AstraZeneca
- 26 Mar 2018 Results of retrospective chart review assessing long-term safety in subset of patients (n=79) published in the Cancer.
- 15 Dec 2017 Status changed from active, no longer recruiting to completed.
- 24 Jul 2017 Planned End Date changed from 1 Dec 2017 to 29 Dec 2017.